
WE CLAIM:

1. A compound of Formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is aryl substituted with 1-2 R^{1a} and 1-2 R^{1b} or monocyclic heteroaryl with 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, and substituted with 1-2 R^{1a} and 1-2 R^{1b};

Ar^2 is aryl substituted with 1-4 R^{2a} or 6-membered heteroaryl with 1-2 nitrogen atoms, and substituted with 1-4 R^{2a};

Ar^3 is aryl substituted with 1-4 R^{3a} or monocyclic heteroaryl with 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur, and substituted with 1-4 R^{3a};

R^{1a} is hydrogen or halo;

R^{1b} is halo, haloalkyl, alkoxy, or haloalkoxy;

R^{2a} is hydrogen, cyano, halo, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkoxy, or haloalkoxy; alternatively, two adjacent R^{2a} groups are taken together with the carbon atoms to which they are attached to form a heterocycle with 1-4 heteroatoms selected from nitrogen, oxygen, and sulfur;

R^{3a} is cyano, halo, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkyl, (R^1R^2N)alkyl, R^1R^2N, alkylC(O)(R^2)Nalkyl, $(alkyl)_2(O)P$, $(alkoxy)_2(O)P$, (alkoxy)(alkyl)(O)P, (alkyl)(O)(NR^1)S, alkylSO_2, or alkylSO_2NH; alternatively, two adjacent R^{3a} groups are taken together with the carbon atoms to which they are attached to form a heterocycle with1-4 heteroatoms selected from nitrogen, oxygen, and sulfur;


R^{4a} or R^{4b} is independently hydrogen, alkyl, alkoxy, hydroxylalkyl, alkoxyalkyl, or haloalkoxy; alternatively, R^{4a} and R^{4b} together with the carbon atom they are both attached to form a C_{3-6} cycloalkyl;

R^{5a} or R^{5b} is independently hydrogen, alkyl, hydroxylalkyl, alkoxyalkyl or haloalkoxyl;

R^1 is hydrogen or alkyl; and

R^2 is hydrogen or alkyl; or R^1R^2N taken together is azetidinyl, oxazolyl pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, and oxo.

2. The compound of claim 1, having Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is phenyl substituted with 1-2 R^{1a} and 1-2 R^{1b} or 6-membered heteroaryl with 1-3 nitrogen atoms and substituted with $1R^{1a}$ and 1-2 R^{1b};

Ar^3 is phenyl substituted with 1-3 R^{3a} or 5- to 6-membered heteroaryl with 1-3 nitrogen atoms and substituted with 1-3 R^{3a};

R^{1a} is hydrogen or halo;

R^{1b} is halo, C_{1-4} haloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

R^{2a} is hydrogen, halo, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

R^{3a} is cyano, halo, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxyalkyl, C_{1-4} haloalkyl, $(R^1R^2N)C_{1-4}$ alkyl, R^1R^2N, C_{1-4} alkyl$C(O)(R^2)NC_{1-4}$ alkyl, $(C_{1-4}$ alkyl$)_2(O)P$, $(C_{1-4}$ alkoxy$)_2(O)P$, $(C_{1-4}$ alkoxy$)(C_{1-4}$ alkyl$)(O)P$, C_{1-4} alkylSO_2, or C_{1-4} alkylSO_2NH;

R^1R^2N taken together is oxazolyl or pyrrolidinyl and is substituted with 0-3 substituents selected from halo, alkyl, and oxo;

R^{4a} or R^{4b} is independently hydrogen, C_{1-4} alkyl, or C_{1-4} hydroxylalkyl; alternatively, R^{4a} and R^{4b} together with the carbon atom they are both attached to form a C_{3-6} cycloalkyl; and


R^{5a} or R^{5b} is independently hydrogen, C_{1-4} alkyl, C_{1-4} hydroxylalkyl, or C_{1-4} alkoxyalkyl.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is phenyl substituted with 1-2 R^{1a} and 1-2 R^{1b}, pyridinyl substituted with 1 R^{1a} and 1-2 R^{1b}, or pyrazinyl substituted with $1R^{1a}$ and 1-2 R^{1b}; and

Ar^3 is phenyl substituted with 1-3 R^{3a}, pyrazolyl substituted with 1-3 R^{3a}, pyridinyl substituted with 1-3 R^{3a}, or pyrimidinyl substituted with 1-3 R^{3a}.

4. The compound of claim 2 or 3, having Formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Ar^1 is phenyl substituted with 1-2 R^{1a} and 1-2 R^{1b}, pyridinyl substituted with 1 R^{1a} and 1-2 R^{1b}, or pyrazinyl substituted with 1 R^{1a} and 1-2 R^{1b};

R^{1a} is hydrogen or halo;

R^{1b} is halo, C_{1-4} haloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;


R^{2a} is hydrogen, halo, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

R^{3a} is cyano, halo, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxyalkyl, C_{1-3} haloalkyl, R^1R^2N, $(C_{1-3}$ alkyl$)_2(O)P$, $(C_{1-3}$ alkoxy$)_2(O)P$, $(C_{1-3}$ alkoxy$)(C_{1-3}$ alkyl$)(O)P$, C_{1-3} alkylSO_2, or C_{1-3} alkylSO_2NH;

R^{4a} or R^{4b} is independently hydrogen, C_{1-3} alkyl, or C_{1-3} hydroxylalkyl; alternatively, R^{4a} and R^{4b} together with the carbon atom they are both attached to form a C_{3-6} cycloalkyl; and

R^{5a} or R^{5b} is independently hydrogen, C_{1-3} alkyl, C_{1-3} hydroxylalkyl, or C_{1-3} alkoxyalkyl.

5. The compound of claim 4, having Formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or F;

R^{1b} is halo, C_{1-2} haloalkyl, or C_{1-2} alkoxy;

R^{2a} is hydrogen, halo, C_{1-3} alkyl, C_{1-3} haloalkyl, or C_{3-6} cycloalkyl;

R^{3a} is halo, hydroxyalkyl, alkoxyalkyl, $(C_{1-2}$ alkyl$)_2(O)P$, $(C_{1-2}$ alkoxy$)_2(O)P$, $(C_{1-2}$ alkoxy$)(C_{1-2}$ alkyl$)(O)P$, C_{1-2} alkylSO_2, or C_{1-2} alkylSO_2NH; and

$R^{3a'}$ is halo.

6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or F;


R^{1b} is F, Cl, or CF_3;

R^{2a} is hydrogen, F, Cl, isopropyl, CF_3, or cyclopropyl;

R^{3a} is $(CH_3)_2(O)P$, $(CH_3CH_2)_2(O)P$, $(CH_3CH_2O)(CH_3)(O)P$, CH_3SO_2, or CH_3SO_2NH; and

$R^{3a'}$ is F.

7. The compound of claim 4, having Formula (VI):



(VI)

or a pharmaceutically acceptable salt thereof, wherein:


R^{1a} is hydrogen or halo;

R^{1b} is halo, C_{1-2} haloalkyl, or C_{1-2} alkoxy;

R^{2a} is hydrogen, halo, C_{1-3} alkyl, or C_{3-6} cycloalkyl;

R^{3a} is $(C_{1-2}$ alkyl$)_2(O)P$, $(C_{1-2}$ alkoxy$)_2(O)P$, $(C_{1-2}$ alkoxy$)(C_{1-2}$ alkyl$)(O)P$, C_{1-2} alkylSO_2, or C_{1-2} alkylSO_2NH.

8. The compound of claim 2 or 3, having Formula (VII):



(VII)

or a pharmaceutically acceptable salt thereof, wherein:

Ar^3 is pyrazolyl substituted with 1-3 R^{3a}, pyridinyl substituted with 1-3 R^{3a}, or pyrimidinyl substituted with 1-3 R^{3a};

R^{1a} is hydrogen or halo;

R^{1b} is halo, C_{1-4} haloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

R^{2a} is hydrogen, halo, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, or C_{1-4} haloalkoxy;

R^{3a} is cyano, halo, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxyalkyl, $(R^1R^2N)C_{1-4}$ alkyl, R^1R^2N- , $(C_{1-4}$ alkyl$)_2(O)P$, $(C_{1-4}$ alkoxy$)_2(O)P$, $(C_{1-4}$ alkoxy$)(C_{1-4}$ alkyl$)(O)P$, C_{1-4} alkylSO_2, or C_{1-4} alkylSO_2NH;


R^1 is hydrogen or alkyl;

R^2 is hydrogen or alkyl; or R^1R^2N taken together is oxazolyl or pyrrolidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, or oxo;

R^{4a} or R^{4b} is independently hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxyalkyl, or C_{1-4} haloalkoxy; R^{4a} and R^{4b} together with the carbon atom they are both attached to form a C_{3-6} cycloalkyl; and

R^{5a} or R^{5b} is independently hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxyalkyl, or C_{1-4} haloalkoxy.

9. The compound of claim 8, having Formula (VIII):



(VIII)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or halo;


R^{1b} is halo, C_{1-2} haloalkyl, or C_{1-2} alkoxy;

R^{2a} is hydrogen, halo, C_{1-3} alkyl, or C_{3-6} cycloalkyl;

R^{3a} is $(C_{1-2}\text{ alkyl})_2(O)P$, $(C_{1-2}\text{ alkoxy})_2(O)P$, $(C_{1-2}\text{ alkoxy})(C_{1-2}\text{ alkyl})(O)P$, C_{1-2} alkylSO_2, or C_{1-2} alkylSO_2NH; and

R^{5a} or R^{5b} is independently hydrogen or C_{1-2} alkyl.

10. The compound of claim 1, having Formula (IX):




(IX)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} is hydrogen or halo;

R^{1b} is halo, C_{1-2} haloalkyl, or C_{1-2} alkoxy;

R^{2a} is hydrogen, halo, C_{1-2} haloalkyl, C_{1-3} alkyl, or C_{3-6} cycloalkyl;

Ar^3 is  ;

R^{3a} is $(C_{1-2}$ alkyl$)_2(O)P$, $(C_{1-2}$ alkoxy$)(C_{1-2}$ alkyl$)(O)P$, or C_{1-2} alkylSO_2NH;

$R^{3a'}$ is halo;

R^{4a} or R^{4b} is independently hydrogen, C_{1-2} alkyl, or C_{1-2} hydroxyalkyl; or R^{4a} and R^{4b} together with the carbon atom to which they are both attached form a C_{3-6} cycloalkyl; and

R^{5a} or R^{5b} is independently hydrogen, C_{1-2} alkyl, C_{1-2} hydroxyalkyl, or C_{1-2} alkoxyalkyl.

11. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein:

R^{4a} is hydrogen;

R^{4b} is hydrogen;

R^{5a} is C_{1-2} alkyl, C_{1-2} hydroxylalkyl, or C_{1-2} alkoxyalkyl; and

R^{5b} is hydrogen.

12. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein:


R^{4a} is C_{1-2} alkyl;

R^{4b} is C_{1-2} alkyl;

R^{5a} is hydrogen; and

R^{5b} is hydrogen.

13. A compound of Formula (I):



(I)

wherein:

Ar^1 is phenyl, pyridinyl, or pyridazinyl and is substituted with 1 halo, haloalkyl or haloalkoxy substituent in the 4-position and 0-2 additional halo or haloalkyl substituents;

Ar^2 is phenyl or pyridinyl and is substituted with 0-2 substituents selected from cyano, fluoro, alkyl, haloalkyl, cycloalkyl, alkoxy, and haloalkoxy;

Ar^3 is phenyl or pyridinyl and is substituted with 0-2 substituents selected from cyano, halo, hydroxyalkyl, alkoxyalkyl, (R^1R^2N)alkyl, $(alkyl)_2(O)P$, $(alkyl)(O)(NR^1)S$, $alkylSO_2$, and $alkylSO_2NH$;

R^1 is hydrogen or alkyl; and

R^2 is hydrogen or alkyl;

or $(R^1)(R^2)N$ taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl and is substituted with 0-3 substituents selected from halo and alkyl;

or a pharmaceutically acceptable salt thereof.










14. A compound of claim 13 where Ar^1 is phenyl substituted with 1 halo, haloalkyl or haloalkoxy substituent in the 4-position and 0-2 additional halo or haloalkyl substituents.




15. A compound of claim 13 where Ar^2 is phenyl substituted with 0 substituents, 1 alkyl or cycloalkyl substituent, or 1-2 fluoro substituents.




16. A compound of claim 13 where Ar^3 is phenyl substituted with 1-2 substituents selected from cyano, halo, hydroxyalkyl, alkoxyalkyl, (R^1R^2N)alkyl, $(alkyl)_2(O)P$, $(alkyl)(O)(NR^1)S$, $alkylSO_2$, and $alkylSO_2NH$.

17. A compound of claim 13 where R^1 is hydrogen and R^2 is hydrogen.







18. A compound of claim 13 selected from the group consisting of













,
,
,
,
,
,
,
,
,
,











,
,
,


,

, and

, or a pharmaceutically acceptable salt thereof.

19. A compound selected from the group consisting of


,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt thereof.

20. A composition comprising a compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

21. A compound according to any one of claims 1-19 or composition according to claim 20 for use in therapy.

22. A compound of any one of claims 1-19 for use in the treatment of heart disease, wherein a therapeutically effective amount of the compound is to be administered to a patient in need thereof.

23. The compound of claim 22 wherein the heart disease is selected from the group consisting of angina pectoris, unstable angina, myocardial infarction, heart failure, acute coronary disease, acute heart failure, chronic heart failure, and cardiac iatrogenic damage.

24. The compound of claim 23 wherein the heart failure is selected from the group consisting of congestive heart failure, systolic heart failure, diastolic heart failure, heart failure with reduced ejection fraction (HF_REF), heart failure with preserved ejection fraction (HF_PEF), acute heart failure, chronic heart failure of ischemic and non-ischemic origin.

25. Use of the compound of any one of claims 1-19 in the manufacture of a medicament for the treatment of heart disease, wherein a therapeutically effective amount of the medicament is to be administered to a patient in need thereof.

26. The use of claim 25 wherein the heart disease is selected from the group consisting of angina pectoris, unstable angina, myocardial infarction, heart failure, acute coronary disease, acute heart failure, chronic heart failure, and cardiac iatrogenic damage.

27. The use of claim 26 wherein the heart failure is selected from the group consisting of congestive heart failure, systolic heart failure, diastolic heart failure, heart failure with reduced ejection fraction (HF_REF), heart failure with preserved ejection fraction (HF_PEF), acute heart failure, chronic heart failure of ischemic and non-ischemic origin.